Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
RASH
MCID: EXN002
MIFTS: 52

Exanthem (RASH)

Categories: Infectious diseases, Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Exanthem

About this section

MalaCards integrated aliases for Exanthem:

Name: Exanthem 11 14 16 75
Exanthema 43
Rash 14

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:0050486
ICD9CM 34 782.1
MeSH 43 D005076
NCIt 49 C111884
SNOMED-CT 68 112625008
ICD10 31 R21
UMLS 71 C0015230
Sources

Summaries for Exanthem

About this section

Disease Ontology: 11 A skin disease that is characterized by a rash that results from a variety of causes including bacteria, viruses, toxins, drugs and autoimmune disorders.

MalaCards based summary: Exanthem, also known as exanthema, is related to viral exanthem and covid-19. An important gene associated with Exanthem is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Prednisone and Menthol have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and bone marrow, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia: 75 An exanthem is a widespread rash occurring on the outside of the body and usually occurring in children.... more...
Sources

Related Diseases for Exanthem

About this section

Diseases in the Exanthem family:

Bacterial Exanthem Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1172)
# Related Disease Score Top Affiliating Genes
1 viral exanthem 32.9 TNF IL6 CRP CD8A CD4
2 covid-19 31.0 TNF IL6 IL2 EGFR CRP CCR6
3 pityriasis rosea 31.0 HLA-B CD8A CD4
4 measles 31.0 IL6 IL2 IFNA1 IFIH1
5 meningitis 30.9 TNF IL6 IL2 HLA-B CRP ALB
6 chickenpox 30.8 TNF IL6 IL2 IFNA1 GPT CTLA4
7 purpura 30.8 TNF IL6 IL2 CRP
8 drug allergy 30.8 HLA-B GPT CYP3A4 CRP CD4 ALB
9 herpes zoster 30.8 PDCD1 IL2 IFNA1 HLA-B CD8A CD4
10 rubella 30.8 TNF IL6 IL2 HLA-B GPT
11 toxic shock syndrome 30.7 TNF IL6 IL2 CRP
12 erythema multiforme 30.7 TNF IL6 IL2
13 allergic disease 30.7 TNF IL6 IL2 ICOSLG H2AC18 CYP3A4
14 scarlet fever 30.7 TNF IL6 CRP CD4 ALB
15 vasculitis 30.7 TNF IL6 HLA-B CTLA4 CRP
16 urticaria 30.7 TNF IL6 CRP CD4
17 chikungunya 30.6 TNF IL6 IFIH1 CRP
18 contact dermatitis 30.6 TNF IL6 IL2 ICOSLG CD8A CD4
19 lymphadenitis 30.6 TNF PDCD1 IL6 ICOSLG CRP CCR6
20 conjunctivitis 30.6 TNF IL6 IL2 HLA-B
21 aseptic meningitis 30.6 TNF IL6 IFNA1 CTLA4 CRP CD8A
22 erythema nodosum 30.6 TNF IL6 CTLA4 CRP
23 spotted fever 30.6 GPT CRP CD4
24 mouth disease 30.6 IL6 IFNA1 IFIH1 H2AC18 CRP CCR6
25 monkeypox 30.6 IFNA1 CD8A CD4
26 pharyngitis 30.6 TNF IL6 GPT CRP CD8A CD4
27 disseminated intravascular coagulation 30.5 TNF IL6 GPT CRP
28 psoriasis 30.5 TNF IL6 IL2 IFIH1 HLA-B CTLA4
29 glomerulonephritis 30.5 TNF IL6 CRP ALB
30 paronychia 30.5 GPT ERBB2 EGFR
31 dermatitis 30.5 TNF IL6 IL2 CTLA4 CCR6
32 hemoglobinopathy 30.5 IL6 GPT CRP CD4 ALB
33 mumps 30.5 TNF IL6 IL2 IFNA1
34 aplastic anemia 30.5 TNF IL6 H2AC18 CYP3A4 CD8A CD4
35 erysipelas 30.5 TNF IL6 IL2 ICOSLG CRP CD8A
36 viral infectious disease 30.5 TNF PDCD1 IL6 IL2 IFNA1 IFIH1
37 myelitis 30.5 TNF IL6 CCR6
38 uveitis 30.4 TNF IL6 IL2 HLA-B CTLA4
39 lung disease 30.4 TNF IL6 IFIH1 H2AC18 CCR6
40 juvenile rheumatoid arthritis 30.4 TNF IL6 IL2 ICOSLG CRP CD4
41 t-cell acute lymphoblastic leukemia 30.4 IL2 ICOSLG H2AC18 CD8A CD4 CCR6
42 meningoencephalitis 30.4 TNF IL6 CRP CD8A CD4 CCR6
43 stomatitis 30.4 TNF IL6 IL2 IFNA1 IFIH1 CD4
44 allergic contact dermatitis 30.4 TNF IL6 IL2 ICOSLG CD8A CD4
45 severe acute respiratory syndrome 30.4 TNF IL6 IL2 IFNA1 IFIH1 GPT
46 dengue disease 30.4 TNF IL6 IFNA1 H2AC18 GPT CD8A
47 scabies 30.4 CD8A CD4 CCR6
48 dermatophytosis 30.4 TNF CD4 CCR6
49 enterocolitis 30.4 TNF IL6 CRP
50 ileus 30.4 TNF IL6 CRP

Graphical network of the top 20 diseases related to Exanthem:



Diseases related to Exanthem
Sources

Symptoms & Phenotypes for Exanthem

About this section

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 ALB CCR6 CD274 CD4 CD8A CRP
2 no effect GR00402-S-2 10.17 ALB CCR6 CD274 CD4 CRP CTLA4

MGI Mouse Phenotypes related to Exanthem:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ALB CCR6 CD274 CD4 CRP CTLA4
2 immune system MP:0005387 10.16 ALB CCR6 CD274 CD4 CD8A CRP
3 endocrine/exocrine gland MP:0005379 10.14 ALB CD4 CD8A CTLA4 EGFR ERBB2
4 normal MP:0002873 10.13 ALB CCR6 CD8A CTLA4 CYP3A4 EGFR
5 liver/biliary system MP:0005370 10.06 ALB CTLA4 EGFR IFIH1 IL2 IL6
6 cardiovascular system MP:0005385 10.06 ALB CCR6 CRP CTLA4 EGFR ERBB2
7 neoplasm MP:0002006 10.04 ALB EGFR ERBB2 IL2 IL6 PDCD1
8 digestive/alimentary MP:0005381 10.02 ALB CD4 CTLA4 EGFR ERBB2 HLA-B
9 hematopoietic system MP:0005397 9.83 CCR6 CD274 CD4 CD8A CTLA4 EGFR
10 respiratory system MP:0005388 9.76 CTLA4 EGFR ERBB2 IFNA1 IL2 IL6
11 mortality/aging MP:0010768 9.47 ALB CD274 CD4 CD8A CTLA4 CYP3A4
Sources

Drugs & Therapeutics for Exanthem

About this section

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 197)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Menthol Approved, Experimental Phase 4 1490-04-6, 2216-51-5, 15356-60-2 1254 16666 165675
3
Tocopherol Approved, Investigational Phase 4 1406-66-2
4
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
5
Nevirapine Approved Phase 4 129618-40-2 4463
6
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
7
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
8
Isotretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4, 4759-48-2 5538 444795 5282379
9
Olaflur Experimental Phase 4 6818-37-7
10
Tocotrienol Investigational Phase 4 6829-55-6 9929901
11 Vitamin K 1 Phase 4
12 Fluorides, Topical Phase 4
13 Anti-Infective Agents Phase 4
14 Fluorides Phase 4
15 Anti-Infective Agents, Local Phase 4
16 Aloe Phase 4
17 Antioxidants Phase 4
18 Tocotrienols Phase 4
19 Tocopherols Phase 4
20 Anti-Retroviral Agents Phase 4
21 Antiviral Agents Phase 4
22 Anti-HIV Agents Phase 4
23 Reverse Transcriptase Inhibitors Phase 4
24
Minocycline Approved, Investigational Phase 3 10118-90-8, 13614-98-7 54675783 5281021
25
Afamelanotide Approved, Investigational Phase 3 75921-69-6 16132954 16197727
26
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 12560
27
Fusidic acid Approved, Investigational Phase 3 6990-06-3 3000226
28
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
29
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
30
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
31
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
32
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
33 Coconut Approved Phase 3
34
Histamine Approved, Investigational Phase 3 51-45-6 774
35
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
36
Desloratadine Approved, Investigational Phase 3 100643-71-8 124087
37
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
38
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
39
Maleic acid Experimental, Investigational Phase 3 110-16-7, 110-17-8 444266 444972
40
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
41 Anti-Bacterial Agents Phase 3
42 Antibiotics, Antitubercular Phase 3
43 Gastrointestinal Agents Phase 3
44 Protein Kinase Inhibitors Phase 3
45 Provitamins Phase 3
46 Erythromycin stearate Phase 3
47 Erythromycin Ethylsuccinate Phase 3
48 Erythromycin Estolate Phase 3
49 Antineoplastic Agents, Hormonal Phase 3
50 Hormones Phase 3

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
2 Esthetic Effect of Casein Phosphopeptide-Amorphous Calcium Phosphate Varnish Versus Tricalcium Phosphate Varnish on Postorthodontic White Spot Lesions: A Randomized Pilot Study Unknown status NCT03217084 Phase 4 MI varnish GC;White varnish 3M
3 White Spot Lesion Development in Post-orthodontic Patients Following Weekly Application of a 1.25% Fluoride Gel Compared to Placebo Over 6 Months Completed NCT01329731 Phase 4 elmex® gelée;negative control (placebo)
4 Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
5 Randomized Controlled Trial Comparing the Efficacy and Safety of Calmoseptine Ointment and Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Completed NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
6 A Parallel, Evaluator-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Two Marketed Topical Skin Protectants Containing Zinc Oxide in Children With Diaper Rash Completed NCT00219466 Phase 4
7 A Multi-center, Double-blinded Randomized Trial for Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
8 A Multicenter, Randomized, Open-label, Controlled Study of Nevirapine (VIRAMUNE®) and a Short Course of Prednisone to Determine the Safety and Effectiveness of This Strategy in Preventing Nevirapine (VIRAMUNE®) Associated Rash. Completed NCT02184299 Phase 4 Nevirapine;Prednisone
9 A Randomized Control Trial to Compare Doxycycline to Isotretinoin for the Treatment of Acneiform Eruptions in Cancer Patients on Tyrosine Kinase Inhibitors Recruiting NCT04864717 Phase 4 Doxycycline 100mg po once daily x 6 months;Isotretinoin 40 mg po once daily x 6 months
10 The Healthy Baby Bottoms Study: A Trial of Theraworx Foam Formulation for the Prevention and Treatment of Diaper Dermatitis Terminated NCT04101890 Phase 4 Diaper care with Theraworx
11 Pilot Study of Acitretin for Treatment of Erlotinib-induced Skin Rash Withdrawn NCT01299220 Phase 4 Acitretin
12 A Clinical Observation to Assess the Safety and Consumers' Satisfaction of Moussik vs Desitin Creamy Ointment in Prophylaxis of Diaper Rash. A Single Blind, Multicenter, Randomized, Cross-over Study Withdrawn NCT01167465 Phase 4
13 A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE) Completed NCT04704713 Phase 3 Afamelanotide;Placebo
14 Effectiveness of Novel Bioactive Glass in the Treatment of Enamel White Spot Lesions : A Randomized Controlled Trial Completed NCT04401280 Phase 3 BiominF;Novamin;CPP-ACP
15 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Topical Sunscreen to Prevent Erlotinib- or Cetuximab-Induced Skin Rash [or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash] Completed NCT00362986 Phase 3 sunscreen
16 Phase III Randomized Double-Blind Trial of Bepanthen® Cream Versus Cetomacrogol Cream in the Prevention of Papulopustular Eruption in Patients Receiving Epidermal Growth Factor Receptor Inhibitors (EGFRI): BeCet Completed NCT01136005 Phase 3
17 A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
18 A Randomized, Open Label Study to Compare the Use of the Dermatological Creams Verutex, Eritex and Fisiogel in the Management of Skin Rash Associated With Tarceva Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer. Completed NCT00718315 Phase 3 erlotinib [Tarceva];fusidic acid [Verutex];erythromycin [Eritex];Fisiogel
19 A Randomized Controlled Clinical Study Comparing the Efficacy and Safety of Calmoseptine vs Destin Maximum Strength Diaper Rash Paste in Treatment of Incontinence Associated Dermatitis in Older Children and Adults Completed NCT02080247 Phase 3 Skin care regimen with Calmoseptine ointment;Skin care regimen with Destin ointment
20 A Randomized, Double-blind, Prospective Trial of Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in Non-small Cell Lung Cancer Completed NCT01528488 Phase 2, Phase 3
21 Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial Terminated NCT01595893 Phase 3 Oral Vitamin D 3;Miglyol 812 N
22 A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Acute Cutaneous Rash Terminated NCT01529242 Phase 3 Desloratadine + Prednisolone;Dexchlorpheniramine + Betamethasone
23 Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients: A Pilot Study Unknown status NCT03220256 Phase 2 Lamotrigine
24 Caries Prevention Potential of Pearl Powder Versus Casein Phosphopeptide-amorphous Calcium Phosphate on Enamel White Spot Lesions: Randomized Clinical Trial. Unknown status NCT03973554 Phase 2 CPP-ACP
25 A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment. Unknown status NCT01763307 Phase 2 RECONVAL CREAM;PLACEBO
26 Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances Unknown status NCT01729481 Phase 2 Gemcitabine;Erlotinib;Oxaliplatin;Folinic Acid;Irinotecan;5-FU
27 Preemptive Therapy Study of Cetuximab(Erbitux®)Induced Skin Rash Using Doxycycline, Sunscreen, Hydrocortisone and Moisturizer in Colorectal and Head and Neck Cancer Patients Completed NCT01874860 Phase 2 Doxycycline;Hydrocortisone 1% cream;Clindamycin;Medrol-dose pack (Steroid)
28 Phase II, Open-label, Single Blind, Randomised Clinical Trial With Tetracycline as a Prophylaxis for Rash and Dermatological Recommendations Versus Dermatological Recommendations in Patients With NSCLC Receiving Treatment With BIBW 2992 Completed NCT01880515 Phase 2 Tetracycline
29 A Randomized, Double-blind, Placebo-controlled Trial of AC-701 for Treatment of Skin Rash in Subjects With EGFR Inhibitor Therapy Completed NCT04239846 Phase 2 AC-701 Topical Gel 0.3%
30 A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab Completed NCT00332163 Phase 2 Irinotecan;FOLFIRI;Pre-emptive Skin Treatment;Reactive Skin Treatment
31 Double Blind Placebo Controlled Trial, for Evaluating Preventive Therapy With Either Oint Threolone Versus Synthomycine Versus Aqua Cream, for EGFR'I Induced Acneiform Rash Completed NCT01256437 Phase 2 Threolone ointment;ointment Synthomycine;Aqua cream
32 Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor Completed NCT03440515 Phase 2 Prednisone
33 A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer Completed NCT00473083 Phase 2 Minocycline;Clindamycin 2% in hydrocortisone 1% lotion;Erlotinib;Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
34 A Safety, Tolerability and Efficacy Study of Doxycycline Topical Foam Administered Topically for Prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects With Cancer Receiving Cetuximab or Panitumumab Completed NCT02239731 Phase 2 FDX104 (4% Doxycycline)
35 A Two-Part, Phase II Randomized Trial to Explore Topical Spironolactone to Prevent/Attenuate Rash From Epidermal Growth Factor Receptor Inhibitors (Panitumumab and Cetuximab) in Advanced Cancer Patients Completed NCT01867294 Phase 2 Doxycycline;Spironolactone;Sunscreen;Therapeutic Hydrocortisone
36 A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer. Completed NCT00652366 Phase 2 Erlotinib, escalating dose;Erlotinib, standard dose;Gemcitabine
37 A Randomized, Open Label Study to Evaluate the Effect of Doxycycline on Tarceva-induced Skin Rash in Patients With Non-small Cell Lung Cancer After Failure of First Line Chemotherapy Completed NCT00531934 Phase 2 Doxycline;erlotinib [Tarceva]
38 A Phase II Trial Assessing Metronidazol Actavis 1% Topical Cream in the Prevention and Treatment of Erlotinib Associated Rash Completed NCT00642473 Phase 2 Erlotinib;Metronidazole Actavis
39 An Open Label Study of Tarceva in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas : Relationship Between Skin Rash and Survival Completed NCT00461708 Phase 2 Erlotinib;Gemcitabine
40 A Multi-Center Study Investigating the Correlation Between TARCEVA ®-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy Completed NCT01174563 Phase 2 erlotinib [Tarceva]
41 A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for Epidermal Growth Factor Receptor Inhibitor-Induced Papulopustular Eruption Recruiting NCT03115567 Phase 2 Triamcinolone
42 A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of DWP708 Recruiting NCT05378360 Phase 2
43 An Open-label Study for Assessing the Efficacy and Safety of Nicotinamide Treatment for Lupus-associated Skin Lesions in Patients With Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus Active, not recruiting NCT03260166 Phase 2 nicotinamide
44 A Phase 1b/2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of ATR-04 to Reduce the Severity of Epidermal Growth Factor Inhibitor Associated Papulopustular Rash Suspended NCT04731259 Phase 1, Phase 2 ATR-04
45 1% Topical Pimecrolimus Cream for the Prevention of Rash Associated With the Use of the EGFR Antagonist, Cetuximab Terminated NCT01692626 Phase 2 Pimecrolimus;Placebo
46 Four-arm Study to Evaluate Urea 40% Cream, Fluocinonide 0.05% Cream, Tazarotene 0.1% Cream, and an Emollient Cream for the Treatment of Hand-foot Skin Reaction Related to the Use of Multi-targeted Tyrosine Kinase Inhibitor Sorafenib. Terminated NCT00667589 Phase 2 urea 40% cream;fluocinonide 0.05% cream;tazarotene 0.1% cream;bland emollient cream (Udderly smooth® Udder Cream)
47 A Phase II, Randomized, Double-Blind, Parallel Design Study to Evaluate ACZONE™ (Dapsone) Gel, 5% As a Treatment For Rash Related to the Human Epidermal Growth Factor Receptor 1 (HER1)/Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor Tarceva® (Erlotinib) Terminated NCT00343187 Phase 2 ACZONE (dapsone) Gel, 5%;Vehicle Control
48 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects With Cancer Receiving EGFRi or MEKi Therapy Terminated NCT04697069 Phase 2
49 A Phase II Trial of Single-agent Cetuximab Dose Escalated to Rash in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Terminated NCT00082212 Phase 2
50 A Phase 1, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability, and Systemic Absorption of Menadione Topical Lotion as an Emergent and Pre-emergent Treatment for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash Completed NCT00656786 Phase 1 Menadione Topical Lotion

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Sources

Genetic Tests for Exanthem

About this section
Sources

Anatomical Context for Exanthem

About this section

Organs/tissues related to Exanthem:

MalaCards : Skin, Lung, Bone Marrow, Breast, T Cells, Liver, Myeloid
Sources

Publications for Exanthem

About this section

Articles related to Exanthem:

(show top 50) (show all 30820)
# Title Authors PMID Year
1
Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence. 62
36406323 2023
2
Liver protection and hemostatic effects of medicinal plant Arnebia euchroma (Royle) I.M.Johnst extract in a rat model. 62
36126784 2023
3
A Guide to Preclinical Models of Zoster-Associated Pain and Postherpetic Neuralgia. 62
34524508 2023
4
Simian Varicella Virus: Molecular Virology and Mechanisms of Pathogenesis. 62
34669041 2023
5
Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA). 62
36005450 2023
6
Ischemic stroke is a potential complication of uncontrolled inflammation in mevalonate kinase deficiency - A case report. 62
36242899 2022
7
A case of herpes zoster ophthalmicus with optic neuritis of the total length of the optic nerve in the orbital space and ischemic optic neuropathy. 62
36467120 2022
8
First-in-maintenance therapy for localized high-grade osteosarcoma: an open-label phase I/II trial of the anti-PD-L1 antibody ZKAB001. 62
36469563 2022
9
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. 62
36183738 2022
10
Real-life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients. 62
36440690 2022
11
Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study. 62
36107394 2022
12
Efficacy and safety profile of selumetinib in symptomatic inoperable plexiform neurofibromas. 62
35301838 2022
13
Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app. 62
35869671 2022
14
Pityriasis rubra pilaris with erythema gyratum repens-like eruption and resolution with ustekinumab. 62
35978553 2022
15
[Clinical analysis of 49 cases of non-inflammasome related conditions]. 62
36444428 2022
16
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients. 62
35861701 2022
17
PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy. 62
35857126 2022
18
Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. 62
36470213 2022
19
Use of oral fluid samples for the investigation of outbreaks of human parvovirus B19 infection. 62
36149627 2022
20
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. 62
36279618 2022
21
The clinical features of juvenile dermatomyositis: A single-centre inception cohort. 62
36183479 2022
22
Life-threatening chlorpromazine-induced acquired haemophilia A in a patient with a cavernous malformation involving the medulla oblongata. 62
36075795 2022
23
CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma. 62
36074313 2022
24
Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. 62
35108152 2022
25
Residual disease activity and treatment intensification in systemic lupus erythematosus: A cross-sectional study to quantify the need for new therapies. 62
36169280 2022
26
A Boy Presenting with a Fever and Pancytopenia Diagnosed with Systemic Lupus Erythematosus without a Positive Anti-ds-DNA Antibody Result or Hypocomplementemia: A Case Report. 62
36420549 2022
27
First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention. 62
35908264 2022
28
A Diagnostic Prediction Model for Separating Juvenile Idiopathic Arthritis and Chronic Musculoskeletal Pain Syndrome. 62
35460700 2022
29
A Case of Orbital Apex Syndrome as a Complication of Herpes Zoster Ophthalmicus. 62
36413452 2022
30
Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia. 62
36308802 2022
31
Multicentre observational study on multisystem inflammatory syndrome related to COVID-19 in Argentina. 62
36464947 2022
32
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. 62
36264382 2022
33
[A monogenic lupus family caused by homozygous deletions of DNASE1L3 gene and literature review]. 62
36444430 2022
34
Severe Acute Respiratory Syndrome Coronavirus 2-Associated Blepharoconjunctivitis and Erythema Multiforme-Like Rash in a Young Man. 62
36198619 2022
35
A case of erythema multiforme-like rash induced by everolimus in a patient with a pancreatic neuroendocrine tumor. 62
36264476 2022
36
The mixed spongiotic and interface reaction pattern: A study of clinical and histopathologic findings. 62
36445270 2022
37
Varicella Vaccine-Induced Infantile Zoster-Like Skin Rash. 62
36027973 2022
38
Purpuric Vesiculobullous Rash in IgA Vasculitis (IgAV). 62
35970238 2022
39
Persistent Rash After COVID-19 Vaccination: Challenge. 62
36395458 2022
40
Persistent Rash After COVID-19 Vaccination: Answer. 62
36395456 2022
41
A patient with a corticosteroid-resistant pruritic rash. 62
36468817 2022
42
Rash and mucositis. 62
36468504 2022
43
Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis. 62
35352492 2022
44
Perforating Calcinosis Cutis as a Complication of Intraosseous Fluid Infusion in the Setting of a Near-Drowning Event. 62
36461682 2022
45
Hyperkeratotic flexural erythema (more commonly known as granular parakeratosis) with use of laundry sanitizers containing benzalkonium chloride. 62
36164686 2022
46
Clinical analysis of 99 children with Henoch-Schönlein purpura complicated with overt gastrointestinal bleeding. 62
35941339 2022
47
A case report of monkeypox as a result of conflict in the context of a measles campaign. 62
36133748 2022
48
Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management. 62
36460884 2022
49
Anti-MDA5 and anti-SSA/Ro52 antibodies double-positive dermatomyositis overlapping with rheumatoid arthritis-associated interstitial lung disease: A case report. 62
36029141 2022
50
Immune-Related Toxicity Among Adolescent and Young Adult with Melanoma as Compared with the Elderly. 62
35100046 2022
Sources

Variations for Exanthem

About this section
Sources

Expression for Exanthem

About this section
Search GEO for disease gene expression data for Exanthem.
Sources

Pathways for Exanthem

About this section

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.8 CCR6 CD274 CD4 CD8A CRP CTLA4
2
Akt Signaling 64
Show member pathways
 13.36 TNF IL6 IL2 ERBB2 EGFR CD4
3
PAK Pathway 64
Show member pathways
 13.24 CCR6 CD4 EGFR ERBB2 IL2 IL6
4
Toll-like receptor signaling pathway 74
Show member pathways
 12.79 TNF IL6 IL2 IFNA1 IFIH1
5
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.57 TNF IL6 IL2 IFNA1 HLA-B EGFR
6
Immune response IL-23 signaling pathway 22
Show member pathways
 12.5 TNF IL6 IL2 ERBB2 EGFR CD4
7
CD28 co-stimulation 66
Show member pathways
 12.31 PDCD1 ICOSLG CTLA4 CD8A CD4 CD274
8
CD28 Signaling in T-Helper Cell 64
Show member pathways
 12.2 IL2 ICOSLG CTLA4 CD4
9
NF-kappaB Signaling 3
12.07 TNF PDCD1 IL2 IFNA1 IFIH1 CTLA4
10
Spinal cord injury 74
11.95 TNF IL6 IL2 EGFR
11
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.94 CD4 CD8A IL2 IL6 TNF
12
IL27-mediated signaling events 61
Show member pathways
 11.86 TNF IL6 IL2 CD4
13
Allograft rejection 74
11.81 TNF IL2 HLA-B CTLA4
14
T-cell activation SARS-CoV-2 74
Show member pathways
 11.81 TNF PDCD1 IL2 CTLA4 CD8A CD4
15
Phosphorylation of CD3 and TCR zeta chains 66
Show member pathways
 11.73 PDCD1 CD4 CD274
16
Acute viral myocarditis 74
11.7 IL6 IL2 CD4
17
Network map of SARS-CoV-2 signaling pathway 74
Show member pathways
 11.7 IL6 CRP CD8A CD4
18
Th17 cell differentiation pathway 74
11.66 IL6 IL2 CD4
19
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 61
Show member pathways
 11.64 TNF IL2 CTLA4
20
Innate Lymphoid Cells Differentiation 65
11.62 TNF IL2 CD8A CD4 CCR6
21
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.61 TNF IL6 IL2
22
Inflammatory bowel disease signaling 74
Show member pathways
 11.58 TNF IL6 IL2
23
SHP2 signaling 61
11.53 IL6 IL2 EGFR
24
Dendritic Cells Developmental Lineage Pathway 65
11.52 CD4 CD8A IL2 IL6 TNF
25
Interactions between immune cells and microRNAs in tumor microenvironment 74
11.46 PDCD1 CTLA4 CD274
26
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.43 CYP3A4 IL6 TNF
27
Prostaglandin signaling 74
11.2 TNF IL6 IFNA1
28
Cytokines and inflammatory response 74
11.2 TNF IL6 IL2 CD4
29
Immune infiltration in pancreatic cancer 74
11.17 TNF IL6 IL2
30
Cancer immunotherapy by PD-1 blockade 74
11.09 CD274 CD8A PDCD1
31
T cell receptor and co-stimulatory signaling 74
11.08 PDCD1 IL2 CTLA4 CD8A
32
Overview of nanoparticle effects 74
10.98 TNF IL6 CRP
33
Extrafollicular B cell activation by SARS-CoV-2 74
10.95 TNF PDCD1 IL6 IL2 ICOSLG CRP
34
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) 66
10.66 IL2 CTLA4
35
COVID-19 adverse outcome pathway 74
10.66 IL6 IL2
36
Cells and molecules involved in local acute inflammatory response 74
Show member pathways
 10.31 TNF IL6
Sources

GO Terms for Exanthem

About this section

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.03 TNF HLA-B ERBB2 EGFR CTLA4 CD8A
2 plasma membrane GO:0005887 10.03 TNF HLA-B ERBB2 EGFR CTLA4 CD8A
3 external side of plasma membrane GO:0009897 9.53 TNF PDCD1 ICOSLG CTLA4 CD8A CD4

Biological processes related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 10.06 TNF IL2 ERBB2 EGFR CD4
2 immune response GO:0006955 10.06 CCR6 CD274 CD4 CD8A CTLA4 HLA-B
3 positive regulation of kinase activity GO:0033674 9.97 IL2 ERBB2 EGFR CD4
4 humoral immune response GO:0006959 9.96 TNF PDCD1 IL6 IFNA1 CCR6
5 defense response GO:0006952 9.91 TNF IFNA1 ICOSLG HLA-B
6 negative regulation of lipid storage GO:0010888 9.8 CRP IL6 TNF
7 immune system process GO:0002376 9.61 PDCD1 IL2 IFIH1 ICOSLG HLA-B CTLA4
8 adaptive immune response GO:0002250 9.58 PDCD1 IL2 IFNA1 ICOSLG HLA-B CTLA4
Sources

Sources for Exanthem

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....